Indivumed and CELLphenomics Announce Partnership for Improved Cancer Patient Care

European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types

12-Sep-2022 - Indivumed GmbH and CELLphenomics GmbH announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to ...

Innovative therapeutic tools in the fight against cancer

Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed

18-May-2021 - Mainz University Medical Center is pleased to announce another spin-off from its ranks: the new biopharmaceutical company KHR Biotech GmbH. The spin-off pursues the goal of developing innovative therapeutic tools in the fight against cancer. The basis for the cooperation is the research success ...

Evotec and Indivumed announce second joint drug discovery programme

23-Jan-2020 - Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”). The final goal of this precision medicine collaboration is to deliver highly ...

Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration

30-Sep-2019 - Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Under the terms of the collaboration agreement, Evotec received full access to the colorectal ...

Evotec and Indivumed announce drug discovery collaboration on precision medicine for colorectal cancer

12-Apr-2019 - Evotec SE and Indivumed GmbH announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary ...

apceth and Indivumed to Develop Biomarker Platform for Targeted Cellular Therapies

24-Feb-2012 - apceth GmbH & Co. KG and Indivumed GmbH have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics. The goal is to predict the response of a targeted cellular / gene therapy in ...

Indivumed appoints Dr. Helge Bastian as Managing Director and Chief Commercial Officer

08-Sep-2011 - Indivumed announced that Helge Bastian, Ph.D, will join Indivumed as Managing Director and Chief Commercial Officer on September 12, 2011. Dr. Bastian has over 19 years of international leadership experience in corporations serving the molecular biology, life science research, diagnostics, ...

Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute

Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies

03-Feb-2010 - Indivumed GmbH has been awarded a subcontract by SAIC-Frederick, Inc., under its prime contract with the U.S. National Cancer Institute (NCI) to assess the impact of sampling procedures on the integrity of cancer biospecimens and key data derived from them. The NCI’s Office of Biorepositories and ...

Inostics acquires from Johns Hopkins University an exclusive license for detection of PIK3CA

Subsidiary of Indivumed aims to develop DNA-based blood tests for individualizing cancer therapy

16-Nov-2009 - Inostics GmbH announced it has obtained a world-wide exclusive license for detection of PIK3CA mutations from Johns Hopkins University (Baltimore, MD). The license grants Inostics, a subsidiary of Indivumed, the exclusive right to use digital PCR techniques and other technologies such as ...

Indivumed appoints Harald Eistetter as Chief Business Officer and Managing Director

04-Feb-2008 - Indivumed GmbH announced the appointment of Harald R Eistetter, PhD, as Managing Director and to the newly created position of Chief Business Officer. Dr Eistetter, who has more than two decades of leadership experience in the pharmaceutical and biotech industry, will be responsible in ...